New Zealand markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
135.42-5.45 (-3.87%)
At close: 04:00PM EDT
135.00 -0.42 (-0.31%)
After hours: 07:59PM EDT

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
45 44 44 88 88

Full-time employees66,015

Key executives

NameTitlePayExercisedYear born
Mr. Lars Fruergaard JorgensenPresident, CEO & Member of Management Board4.72MN/A1966
Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board1.87MN/A1971
Mr. Henrik Ehlers WulffExecutive VP of Product Supply, Quality & IT and Member of the Management Board1.89MN/A1970
Ms. Camilla SylvestExecutive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board1.84MN/A1972
Dr. Martin Holst LangeExecutive VP of Development & Member of the Management Board1.78MN/A1970
Dr. Marcus Schindler Ph.D.EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board1.78MN/A1966
Mr. Maziar Mike DoustdarExecutive VP of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExecutive VP of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExecutive VP, Head of Rare Disease & Member of Management BoardN/AN/A1974
Ms. Tania SabroeExecutive VP of Global People & Organisation and Member of Management BoardN/AN/A1977
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 1 July 2024 is 1. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.